Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 18 min ago
PreprintCC BY-NCbioRxiv

Microglia transcriptomic response to doxorubicin-induced genotoxic stress

  1. 1Mahidol University

Abstract

Chemobrain, characterized by cognitive dysfunction, has emerged as a significant health concern following cancer treatment. Doxorubicin, an FDA-approved chemotherapeutic agent, is widely used to treat various cancers. However, its adverse effects raise concerns regarding toxicity in non-cancerous cell types. Microglia, the resident immune cells of the brain, play a central role in maintaining neural homeostasis. Despite this, the mechanisms by which microglia become dysfunctional following doxorubicin exposure remain poorly understood. Understanding the transcriptomic alterations induced by doxorubicin in microglia could provide critical insights into mechanisms underlying its neurotoxic effects. In this study, the transcriptomic response of human microglia to doxorubicin using mRNA sequencing combined with bioinformatic analysis was investigated. Exposure to doxorubicin significantly altered microglial morphology, promoting a shift toward a process-bearing phenotype in human HMC3 cells. This phenotypic change was accompanied by elevated levels of DNA damage and was associated with the induction of cellular senescence. At the gene regulation level, the Illumina-based transcriptomic analysis provided 25,834 gene expression profiling in which 5,669 were differentially expressed. The future analyses revealed that 3,431 (upregulated) and 2,238 (downregulated) were differentially expressed under the treatment of doxorubicin. Genes associated with the p53 signaling pathway and inflammatory responses were upregulated, whereas genes involved in translation, DNA replication, and cell-cycle progression were downregulated. This transcriptional dysregulation was accompanied by differential expression of key transcription factors. This study provides transcriptomic evidence elucidating the genotoxic response to doxorubicin in microglial cells, offering mechanistic insights into chemobrain and highlighting key molecular pathways as potential targets for therapeutic intervention.

Related

  1. Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Deoxynivalenol increases cell vulnerability to genotoxic stress through translational depletion of DNA damage response proteins
    Chloé Huertas, Marion Beaupère, Odile Burlet-Schiltz +6
    HALPreprintPublisher termsFull textProteomics & metabolomicsGeneral biologyHAL
  3. Empagliflozin does not rescue nor exacerbate doxorubicin-induced skeletal muscle wasting and metabolic dysfunction in male mice
    Birgit Van Asbroeck, Dorien Dombrecht, Sebastiaan Dalle +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPhysiologyCrossref
  4. Extracellular vesicle-encapsulated GDF15 alleviates doxorubicin-induced cardiotoxicity via the SUB1/TERT/TPP signalling axis
    Qingqing Gu, Qianwen Chen, Ye Deng +7
    Communications BiologyPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicineCrossref
  5. Nanocurcumin Attenuates Doxorubicin‐Induced Cardiotoxicity by Activating the Wnt/β‐Catenin/GSK‐3β Signaling Axis in Wistar Rats
    Noha A. Alshuwayer, Qamraa H. Alqahtani, Marwa H. Hussein +3
    Journal of Biochemical and Molecular ToxicologyPeer-reviewedCC BY 4.0Full textCardiovascular medicinePMC
BibTeX
@misc{khongkla2026microglia,
  title = {{Microglia transcriptomic response to doxorubicin-induced genotoxic stress}},
  author = {E. Khongkla},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.05.756646},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.05.756646v1},
  note = {CC BY-NC},
}
RIS
TY  - UNPB
TI  - Microglia transcriptomic response to doxorubicin-induced genotoxic stress
AU  - E. Khongkla
PY  - 2026
DA  - 2026/10/05
PB  - bioRxiv
DO  - 10.64898/2026.10.05.756646
UR  - https://www.biorxiv.org/content/10.64898/2026.10.05.756646v1
AB  - Chemobrain, characterized by cognitive dysfunction, has emerged as a significant health concern following cancer treatment. Doxorubicin, an FDA-approved chemotherapeutic agent, is widely used to treat various cancers. However, its adverse effects raise concerns regarding toxicity in non-cancerous cell types. Microglia, the resident immune cells of the brain, play a central role in maintaining neural homeostasis. Despite this, the mechanisms by which microglia become dysfunctional following doxorubicin exposure remain poorly understood. Understanding the transcriptomic alterations induced by doxorubicin in microglia could provide critical insights into mechanisms underlying its neurotoxic effects. In this study, the transcriptomic response of human microglia to doxorubicin using mRNA sequencing combined with bioinformatic analysis was investigated. Exposure to doxorubicin significantly altered microglial morphology, promoting a shift toward a process-bearing phenotype in human HMC3 cells. This phenotypic change was accompanied by elevated levels of DNA damage and was associated with the induction of cellular senescence. At the gene regulation level, the Illumina-based transcriptomic analysis provided 25,834 gene expression profiling in which 5,669 were differentially expressed. The future analyses revealed that 3,431 (upregulated) and 2,238 (downregulated) were differentially expressed under the treatment of doxorubicin. Genes associated with the p53 signaling pathway and inflammatory responses were upregulated, whereas genes involved in translation, DNA replication, and cell-cycle progression were downregulated. This transcriptional dysregulation was accompanied by differential expression of key transcription factors. This study provides transcriptomic evidence elucidating the genotoxic response to doxorubicin in microglial cells, offering mechanistic insights into chemobrain and highlighting key molecular pathways as potential targets for therapeutic intervention.
ER  -